I

Ikena Oncology
D

IKNA

1.71000
USD
-0.01
(-0.29%)
مغلق
حجم التداول
950
الربح لكل سهم
0
العائد الربحي
0
P/E
-1
حجم السوق
82,521,370
الأخبار المقالات

العنوان: Ikena Oncology

القطاع: Healthcare
الصناعة: Biotechnology
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncologyproduct candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.